vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and WOLVERINE WORLD WIDE INC (WWW). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $517.5M, roughly 1.2× WOLVERINE WORLD WIDE INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 6.1%, a 28.3% gap on every dollar of revenue. On growth, WOLVERINE WORLD WIDE INC posted the faster year-over-year revenue change (25.5% vs 4.8%). Over the past eight quarters, WOLVERINE WORLD WIDE INC's revenue compounded faster (14.5% CAGR vs 4.6%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Wolverine World Wide is a global designer, manufacturer and marketer of branded footwear, apparel and accessories. It owns popular brands including Merrell, Sperry, Saucony and Hush Puppies, serving outdoor, casual, workwear and athletic segments via e-commerce, retail stores and global wholesale networks.
RPRX vs WWW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $517.5M |
| Net Profit | $214.2M | $31.8M |
| Gross Margin | — | 47.3% |
| Operating Margin | 62.4% | 9.7% |
| Net Margin | 34.4% | 6.1% |
| Revenue YoY | 4.8% | 25.5% |
| Net Profit YoY | 2.9% | 162.8% |
| EPS (diluted) | $0.49 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $517.5M | ||
| Q4 25 | $622.0M | — | ||
| Q3 25 | $609.3M | $470.3M | ||
| Q2 25 | $578.7M | $474.2M | ||
| Q1 25 | $568.2M | $412.3M | ||
| Q4 24 | $593.6M | $494.7M | ||
| Q3 24 | $564.7M | $440.2M | ||
| Q2 24 | $537.3M | $425.2M |
| Q1 26 | — | $31.8M | ||
| Q4 25 | $214.2M | — | ||
| Q3 25 | $288.2M | $25.1M | ||
| Q2 25 | $30.2M | $26.8M | ||
| Q1 25 | $238.3M | $12.1M | ||
| Q4 24 | $208.2M | $23.1M | ||
| Q3 24 | $544.0M | $23.2M | ||
| Q2 24 | $102.0M | $13.8M |
| Q1 26 | — | 47.3% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 47.5% | ||
| Q2 25 | — | 47.2% | ||
| Q1 25 | — | 47.2% | ||
| Q4 24 | — | 43.4% | ||
| Q3 24 | — | 45.1% | ||
| Q2 24 | — | 43.1% |
| Q1 26 | — | 9.7% | ||
| Q4 25 | 62.4% | — | ||
| Q3 25 | 70.1% | 8.4% | ||
| Q2 25 | 36.3% | 8.6% | ||
| Q1 25 | 94.0% | 4.8% | ||
| Q4 24 | 60.9% | 7.4% | ||
| Q3 24 | — | 7.9% | ||
| Q2 24 | 50.2% | 6.8% |
| Q1 26 | — | 6.1% | ||
| Q4 25 | 34.4% | — | ||
| Q3 25 | 47.3% | 5.3% | ||
| Q2 25 | 5.2% | 5.7% | ||
| Q1 25 | 41.9% | 2.9% | ||
| Q4 24 | 35.1% | 4.7% | ||
| Q3 24 | 96.3% | 5.3% | ||
| Q2 24 | 19.0% | 3.2% |
| Q1 26 | — | $0.37 | ||
| Q4 25 | $0.49 | — | ||
| Q3 25 | $0.67 | $0.30 | ||
| Q2 25 | $0.07 | $0.32 | ||
| Q1 25 | $0.55 | $0.15 | ||
| Q4 24 | $0.46 | $0.29 | ||
| Q3 24 | $1.21 | $0.28 | ||
| Q2 24 | $0.23 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | — |
| Total DebtLower is stronger | $9.0B | $621.7M |
| Stockholders' EquityBook value | $9.7B | $408.0M |
| Total Assets | $19.6B | $1.7B |
| Debt / EquityLower = less leverage | 0.92× | 1.52× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $618.7M | — | ||
| Q3 25 | $938.9M | — | ||
| Q2 25 | $631.9M | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $929.0M | — | ||
| Q3 24 | $950.1M | — | ||
| Q2 24 | $1.8B | — |
| Q1 26 | — | $621.7M | ||
| Q4 25 | $9.0B | — | ||
| Q3 25 | $8.9B | $676.4M | ||
| Q2 25 | $8.0B | $708.5M | ||
| Q1 25 | $7.6B | $710.8M | ||
| Q4 24 | $7.6B | $648.0M | ||
| Q3 24 | $7.6B | $702.8M | ||
| Q2 24 | $7.6B | $814.7M |
| Q1 26 | — | $408.0M | ||
| Q4 25 | $9.7B | — | ||
| Q3 25 | $9.6B | $376.7M | ||
| Q2 25 | $9.5B | $344.0M | ||
| Q1 25 | $9.8B | $310.6M | ||
| Q4 24 | $10.3B | $312.9M | ||
| Q3 24 | $10.3B | $295.2M | ||
| Q2 24 | $9.8B | $262.1M |
| Q1 26 | — | $1.7B | ||
| Q4 25 | $19.6B | — | ||
| Q3 25 | $19.3B | $1.7B | ||
| Q2 25 | $18.3B | $1.8B | ||
| Q1 25 | $17.6B | $1.7B | ||
| Q4 24 | $18.2B | $1.7B | ||
| Q3 24 | $18.0B | $1.8B | ||
| Q2 24 | $17.7B | $1.8B |
| Q1 26 | — | 1.52× | ||
| Q4 25 | 0.92× | — | ||
| Q3 25 | 0.93× | 1.80× | ||
| Q2 25 | 0.84× | 2.06× | ||
| Q1 25 | 0.78× | 2.29× | ||
| Q4 24 | 0.74× | 2.07× | ||
| Q3 24 | 0.74× | 2.38× | ||
| Q2 24 | 0.78× | 3.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | $146.2M |
| Free Cash FlowOCF − Capex | — | $145.6M |
| FCF MarginFCF / Revenue | — | 28.1% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | 3.86× | 4.60× |
| TTM Free Cash FlowTrailing 4 quarters | — | $125.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $146.2M | ||
| Q4 25 | $827.1M | — | ||
| Q3 25 | $702.6M | $33.0M | ||
| Q2 25 | $364.0M | $44.6M | ||
| Q1 25 | $596.1M | $-83.8M | ||
| Q4 24 | $742.5M | $82.4M | ||
| Q3 24 | $703.6M | $108.2M | ||
| Q2 24 | $658.2M | $26.7M |
| Q1 26 | — | $145.6M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $30.1M | ||
| Q2 25 | — | $41.2M | ||
| Q1 25 | — | $-91.4M | ||
| Q4 24 | — | $74.4M | ||
| Q3 24 | — | $104.1M | ||
| Q2 24 | — | $23.7M |
| Q1 26 | — | 28.1% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | -22.2% | ||
| Q4 24 | — | 15.0% | ||
| Q3 24 | — | 23.6% | ||
| Q2 24 | — | 5.6% |
| Q1 26 | — | 0.1% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 0.7% |
| Q1 26 | — | 4.60× | ||
| Q4 25 | 3.86× | — | ||
| Q3 25 | 2.44× | 1.31× | ||
| Q2 25 | 12.06× | 1.66× | ||
| Q1 25 | 2.50× | -6.93× | ||
| Q4 24 | 3.57× | 3.57× | ||
| Q3 24 | 1.29× | 4.66× | ||
| Q2 24 | 6.45× | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
WWW
| Sales Channel Through Intermediary | $230.2M | 44% |
| Sales Channel Directly To Consumer | $142.6M | 28% |
| Work Group | $134.0M | 26% |
| Other | $10.7M | 2% |
